Background and Challenge
A mid-size specialty pharmaceutical company with a leading respiratory brand (RespiraFlow, an inhaled corticosteroid/LABA combination for moderate-to-severe asthma) faced a growing disconnect between speaker program spending and measurable commercial impact. The brand was running 280 speaker programs annually at a total cost of $4.2 million, making it the single largest line item in the peer-to-peer marketing budget. Yet the brand team could not answer a basic question: were these programs actually driving prescriptions?
The speaker program operation had grown organically over the five years since the brand's launch. Each of the six regional sales directors had discretion to schedule programs in their regions, choosing venues, speakers, and formats based on local preferences and historical practice. There was no centralized venue selection process, no standardized format, no consistent measurement methodology, and no requirement to demonstrate ROI for individual programs.
The problems were compounding. Program costs had increased 22% year-over-year, driven primarily by escalating venue costs (many programs were held at upscale restaurants with high per-person food and beverage minimums) and growing speaker honorarium demands from high-profile pulmonologists. At the same time, attendance was declining: average attendance had dropped from 14 HCPs per program three years ago to 9.5 HCPs per program in the most recent quarter. And the brand team suspected that the same physicians were attending multiple programs, meaning incremental reach was minimal.
"We were spending $4.2 million a year on speaker programs and the only metric we tracked was whether the event happened. We had no idea which programs drove prescribing, which were wasted money, or whether the entire investment was justified." — Senior Brand Manager, Respiratory Franchise
The Approach
The brand team undertook a 12-month initiative to restructure the speaker program portfolio, guided by three principles: measure everything, optimize for ROI, and maintain HCP value. The initiative was structured in three phases.
Phase 1: Measurement and Diagnosis (Months 1-3)
The first priority was building a measurement framework that could attribute prescribing impact to individual speaker programs. The team implemented a methodology that matched attendee lists (captured through Veeva Events) to prescription data (IQVIA Xponent) using NPI matching. They measured TRx and NRx for each attending HCP in the 60-day window before and after the program, comparing prescribing changes to a matched control group of non-attending HCPs with similar baseline prescribing profiles.
The results of this diagnostic analysis were eye-opening. The 280 programs fell into a clear distribution: approximately 30% of programs generated strong script lift (15%+ NRx increase among attendees), 40% produced moderate lift (5-15% increase), and 30% showed negligible or no measurable impact (less than 5% increase, not statistically distinguishable from control). The bottom 30% of programs were consuming roughly $1.3 million in budget with essentially no commercial return.
Phase 2: Optimization Initiatives (Months 4-9)
Armed with the diagnostic data, the team implemented four key optimization initiatives:
1. Data-Driven Venue Selection. The team analyzed venue characteristics across all 280 programs to identify patterns associated with higher attendance and script lift. They found that programs held at mid-range restaurants with private dining rooms had 25% higher attendance than programs at high-end restaurants (where per-person costs were 2-3x higher). They also found that programs held on Tuesday through Thursday evenings had 35% higher attendance than Monday or Friday events. Based on these findings, the team centralized venue selection using a standardized venue scorecard that rated restaurants on cost, accessibility, parking, private room quality, and geographic proximity to target HCP clusters.
2. Virtual Hybrid Format. The team introduced a virtual-hybrid option for programs where geographic dispersion of target HCPs made in-person attendance difficult. Rather than requiring all attendees to travel to a single restaurant, the hybrid format offered an in-person experience for nearby HCPs and a simultaneous virtual option for those further away. The hybrid programs reduced venue and catering costs by 45% per program while increasing total attendance by 40% compared to purely in-person events.
3. KOL Tiering and Speaker Optimization. The brand had been using 42 different speakers across the 280 programs, with significant variation in speaking effectiveness. The team analyzed each speaker's script lift data (the prescribing impact of programs where they spoke) and tiered them into three categories: Tier 1 speakers (12 physicians) who consistently generated top-quartile script lift, Tier 2 speakers (18 physicians) who produced average results, and Tier 3 speakers (12 physicians) whose programs underperformed. The team concentrated 70% of speaking engagements on Tier 1 speakers, 25% on Tier 2, and phased out Tier 3 speakers over two quarters.
4. Attendee Targeting and Deduplication. The team implemented pre-program attendee screening to prioritize HCPs who had not previously attended a program and who had high prescribing potential but had not yet prescribed RespiraFlow. They reduced duplicate attendance (HCPs attending more than two programs per year) from 28% of total attendance to 12%, freeing capacity for new HCP exposure.
Phase 3: Scaling and Governance (Months 10-12)
The final phase focused on institutionalizing the changes through updated standard operating procedures, a speaker program governance committee that reviewed program proposals before approval, and a monthly ROI reporting dashboard that tracked cost per attendee, cost per new prescriber, and script lift by program and by speaker.
Results
The restructured speaker program portfolio delivered measurable improvements across every key metric:
| Metric | Before (FY2025) | After (FY2026) | Change |
|---|---|---|---|
| Total Programs | 280 | 220 | -21% (fewer, higher quality) |
| Total Spend | $4.2M | $2.9M | -30% |
| Cost per Program | $15,000 | $13,200 | -12% |
| Avg. Attendance per Program | 9.5 HCPs | 13.3 HCPs | +40% |
| Unique HCPs Reached | 1,820 | 2,340 | +29% |
| Duplicate Attendance Rate | 28% | 12% | -16 pts |
| Avg. Script Lift per Program | +8.2% | +9.4% | +15% |
| Cost per New Prescriber | $4,800 | $3,100 | -35% |
| Revenue per Dollar Spent | $5.40 | $8.20 | +52% |
| Speaker Count | 42 | 26 | -38% (concentrated on top performers) |
| % Hybrid Programs | 0% | 35% | New format |
The most striking result was the simultaneous cost reduction and effectiveness improvement. By eliminating the bottom 30% of underperforming programs, centralizing venue selection, and concentrating speaking engagements on the most effective KOLs, the brand reduced total spending by 30% while improving every quality metric. The shift to a 35% hybrid program mix was particularly impactful: hybrid programs cost 40% less per attendee while reaching HCPs who would not have attended in-person events due to geographic distance or scheduling conflicts.
The script lift improvement from 8.2% to 9.4% per program, while seemingly modest in percentage terms, translated to significant commercial impact when multiplied across 220 programs and 2,340 unique HCP attendees. The estimated incremental TRx volume attributable to the improved script lift was 1,850 prescriptions over the 12-month period, representing approximately $1.4 million in incremental net revenue.
Combined with the $1.3 million in cost savings, the total financial impact of the restructuring was $2.7 million in improved speaker program economics. The revenue-per-dollar-spent metric improved from $5.40 to $8.20, a 52% improvement in program ROI.
"The biggest insight was not that we were spending too much. It was that we were spending in the wrong places. One-third of our programs were essentially social events for physicians who were already prescribing our product. By redirecting that spend toward programs targeting non-prescribers with high potential, we got dramatically more value from a smaller budget." — Director of Commercial Excellence
Key Takeaways
Lessons Learned
- Measure before you cut. The team did not start by reducing programs. They started by measuring which programs worked and which did not. This data-driven diagnosis gave them the confidence to make targeted cuts rather than across-the-board reductions that would have damaged high-performing programs along with underperforming ones.
- Venue selection matters more than you think. The correlation between venue cost and program effectiveness was actually negative: the most expensive venues produced lower attendance and lower script lift. Mid-range restaurants with good private dining rooms and convenient locations outperformed high-end venues on every metric.
- Speaker quality is not uniform. The 12 Tier 1 speakers generated 2.3x the script lift of Tier 3 speakers. Concentrating engagements on top performers and phasing out underperformers was the single highest-impact optimization.
- Hybrid formats expand reach without sacrificing quality. The assumption that virtual attendees would be less engaged than in-person attendees proved false. Virtual attendees showed similar script lift rates to in-person attendees at the same programs, likely because the clinical content quality was the same regardless of attendance mode.
- Deduplication frees capacity for new HCPs. Reducing repeat attendance from 28% to 12% allowed the team to expose 520 additional unique HCPs to the program content without increasing total attendance slots. These new HCPs were the primary source of new prescriber acquisition.
The restructured speaker program is now the brand's most efficient peer-to-peer marketing channel on a cost-per-new-prescriber basis. The governance framework and monthly ROI reporting ensure that program quality is maintained and that the team can identify and address underperformance before it accumulates. The approach is being adopted by two additional brands in the company's portfolio in 2026.
Try the Tools Used in This Case Study
Measure and optimize your own speaker program ROI with our free calculators.